Flex Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.flex-pharma.com
Clinical Trials
5
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS
Phase 1
Withdrawn
- Conditions
- Amyotrophic Lateral SclerosisFasciculation
- Interventions
- Drug: FLX-787-ODT (orally disintigrating tablet)
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Flex Pharma, Inc.
- Registration Number
- NCT03338114
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Flex Pharma, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03334786
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.
Phase 2
Terminated
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- Drug: FLX-787-ODT (orally disintegrating tablet)Drug: Placebo ODT
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Flex Pharma, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03254199
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Hospital for Special Care, New Britain, Connecticut, United States
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.
Phase 2
Terminated
- Conditions
- Motor Neuron Disease
- Interventions
- Drug: Placebo ODTDrug: FLX-787-ODT (orally disintegrating tablet)
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Flex Pharma, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03196375
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸California Pacific Medical Center, Sacramento, California, United States
News
No news found